Walker Chandiok & Co LLP

Walker Chandiok & Co LLP

Unit No. 02, Second Floor,
BPTP Capital City,
Plot No – 2B, Sector-94, Noida,
Gautam Buddha Nagar - 201301
Uttar Pradesh, India

T +91 120 485 5999
F +91 120 485 5902

Independent Auditor's Review Report on Standalone Unaudited Quarterly Financial Results of the Jubilant Pharmova Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Jubilant Pharmova Limited

1. We have reviewed the accompanying statement of standalone unaudited financial results ('the Statement') of Jubilant Pharmova Limited ('the Company') for the quarter ended 30 June 2026, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations').

2. The Statement, which is the responsibility of the Company's management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting ('Ind AS 34'), prescribed under section 133 of the Companies Act, 2013 ('the Act'), and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with the Standards on Auditing specified under section 143(10) of the Act, and consequently, does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

CHANDIOK & CO LLP * SURNAME CHARTERED ACCOUNTANTS * WALKER

4. Based on our review conducted as above nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34, prescribed under section 133 of the Act, and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in accordance with the requirements of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Walker Chandiok & Co LLP
Chartered Accountants
Firm Registration No: 001076N/N500013

WALKER CHANDIOK & CO LLP * CHARTERED ACCOUNTANTS *

Ashish Gupta
Partner
Membership No.: 504662
UDIN: 26504662TMHFBZ6243

Place: Noida
Date: 10 August 2026

Jubilant Pharmova Limited

Regd. Office: Bhartiagram, Gajraula, Distt. Amroha-244 223 (U.P.)

CIN:L24116UP1978PLC004624

Website: www.jubilantpharmova.com, Email: investors@jubl.com, Tel: +91-5924-267437

Statement of Standalone Unaudited Financial Results for the Quarter ended 30 June 2026

(₹ in million)

Sr. No.	Particulars	Quarter Ended			Year Ended
		30 June 2026	31 March 2026	30 June 2025	31 March 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	CONTINUING OPERATIONS				
1	**Revenue from operations**				
	a) Sales/Income from operations	671	703	595	2,634
	b) Other operating income	-	-	-	1
	Total revenue from operations	671	703	595	2,635
2	Other income	1	5	7	24
3	**Total income (1+2)**	672	708	602	2,659
4	**Expenses**				
	a) Employee benefits expense	283	248	232	1,038
	b) Finance costs	9	9	30	73
	c) Depreciation and amortisation expense	14	13	15	60
	d) Other expenses	268	310	260	1,109
	Total expenses	574	580	537	2,280
5	**Profit before exceptional items and tax (3-4)**	98	128	65	379
6	Exceptional items	-	87	-	87
7	**Profit before tax (5-6)**	98	41	65	292
8	**Tax expense**				
	- Current tax	20	2	12	46
	- Deferred tax charge/(credit)	5	(533)	12	47
	Total tax expense/(benefit)	25	(531)	24	93
9	**Profit for the period from continuing operations (7-8)**	73	572	41	199
	DISCONTINUED OPERATIONS				
	Profit from discontinued operations	-	-	26	43
	Tax expense/(benefit) of discontinued operations	-	-	9	(390)
10	**Profit after tax from discontinued operations**	-	-	17	433
11	**Profit for the period (9+10)**	73	572	58	632
12	**Other comprehensive income/(loss)**				
	A) In respect of continuing operations				
	a) Items that will not be reclassified to profit or loss	1	1	(1)	-
	b) Income tax relating to items that will not be reclassified to profit or loss	-	(2)	-	(1)
	Sub total	1	(1)	(1)	(1)
	B) In respect of discontinued operations				
	a) Items that will not be reclassified to profit or loss	-	-	-	(12)
	b) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	4
	Sub total	-	-	-	(8)
	Other comprehensive income/(loss) for the period	1	(1)	(1)	(9)
13	**Total comprehensive income for the period (11+12)**	74	571	57	623
14	**Earnings per share of ₹ 1 each (not annualized for the quarters) (for continuing operations)**				
	Basic (₹)	0.46	3.59	0.26	1.25
	Diluted (₹)	0.46	3.59	0.26	1.25
	Earnings per share of ₹ 1 each (not annualized for the quarters) (for discontinued operations)				
	Basic (₹)	-	-	0.10	2.72
	Diluted (₹)	-	-	0.10	2.72
	Earnings per share of ₹ 1 each (not annualized for the quarters) (for continuing and discontinued operations)				
	Basic (₹)	0.46	3.59	0.36	3.97
	Diluted (₹)	0.46	3.59	0.36	3.97
15	Paid-up equity share capital (face value per share ₹ 1)	159	159	159	159
16	Reserves excluding revaluation reserves (other equity)				22,964
	See accompanying notes to the Standalone Unaudited Financial Results				

Jubilant Pharmova Limited
Notes to the Standalone Unaudited Financial Results

1. These standalone unaudited financial results have been prepared in accordance with Indian Accounting Standards ("Ind AS") prescribed under Section 133 of the Companies Act, 2013 and other accounting principles generally accepted in India and is in compliance with the presentation and disclosure requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

2. In accordance with Ind AS 108 "Operating Segments", segment information has been provided in the consolidated unaudited financial results of the Group and therefore no separate disclosure on segment information is given in these standalone unaudited financial results.

3. The figures for the preceding quarter ended 31 March 2026, as reported in these standalone unaudited financial results, are the balancing figures between audited figures in respect of the full financial year and the published year to date figures until the end of third quarter of that financial year. Also, the figures until the end of the third quarter had only been reviewed and not subjected to audit. Further, previous period figures have been regrouped / reclassified to conform to the current period's classification.

4. The above standalone unaudited financial results were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10 August 2026. These results have been subjected to limited review by the Statutory Auditors of the Company. The review report of the Statutory Auditors is being filed with BSE Limited and National Stock Exchange of India Limited. For more details on standalone unaudited results, visit Investors section of our website at www.jubilantpharmova.com and Financial Results at Corporates section of www.nseindia.com and www.bseindia.com.

For Jubilant Pharmova Limited

PRIYAVRAT BHARTIA Digitally signed by PRIYAVRAT BHARTIA Date: 2026.08.10 18:46:35 +05'30'

Place : New Delhi
Date : 10 August 2026

Priyavrat Bhartia
Managing Director